Biosimilar medicines and cost-effectiveness

Figures & data

Figure 1 Outline of biotechnology medicines.

Figure 2 Top 10 biopharmaceuticals in sales in 2006.⁴¹

Abbreviation: G-CSF, granulocyte colony-stimulating factor.

Figure 3 The cost-effectiveness plane.

Table 1 Threshold incremental cost-effectiveness ratios in selected countries

Country	Threshold value in local currency	Threshold value in Euro
Australia^Citation35	AUS$42,000–$76,000 per life year	€24,700–€44,700 per life year
Canada^Citation36	CAN$20,000–$100,000 per QALY	€12,700–€63,300 per QALY
England/Wales^Citation37	£20,000–£30,000 per QALY	€22,800–€34,100 per QALY
Netherlands^Citation38	€20,000–€80,000 per QALY	€20,000–€80,000 per QALY
New Zealand^Citation39	NZ$3000–15,000 per QALY	€1400–€7200 per QALY
United States^Citation40	US$50,000 per QALY	€34,400 per QALY

Notes: Local threshold values were converted into Euro using market exchange rates.

Abbreviation: QALY, quality-adjusted life year.

IMS HealthMidas DatabaseLondon, UKIMS Health2008

 Google Scholar

GeorgeBHarrisAMitchellACost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia (1991 to 1996)Pharmacoeconomics200119111103110911735677

 PubMed Web of Science ®Google Scholar

LaupacisAFeenyDDetskyASTugwellPXHow attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluationsCMAJ199214644734811306034

 PubMed Web of Science ®Google Scholar

RafteryJReview of NICE’s recommendations, 1999–2005BMJ200633275521266126816735341

 PubMed Web of Science ®Google Scholar

Health Care Insurance BoardRichtlijnen voor farmaco-economisch onderzoek (Guidelines for Pharmaco-Economic Research)Amstelveen, The NetherlandsHealth Care Insurance Board1999

 Google Scholar

PHARMACPrescription for Pharmacoeconomic Analysis: Methods for Cost-Utility AnalysisAuckland, NZPHARMAC2007

 Google Scholar

GrosseSDAssessing cost-effectiveness in healthcare: history of the $50,000 per QALY thresholdExpert Rev Pharmacoecon Outcomes Res20088216517820528406

 PubMedGoogle Scholar